Amgen

Citing appeals court 'anarchy,' Amgen asks SCOTUS to weigh its PCSK9 patent spat with Sanofi
Citing appeals court 'anarchy,' Amgen asks SCOTUS to weigh its PCSK9 patent spat with Sanofi
Fierce Pharma
Amgen
Sanofi
Regeneron
PCSK9 inhibitors
Supreme Court
Praluent
Repatha
Flag link:
Two Pharma Giants Successfully Navigate a Challenging Climate
Two Pharma Giants Successfully Navigate a Challenging Climate
Yahoo/Zacks.com
Donald Trump
drug pricing
Merck
Amgen
Flag link:
Clover Initiates Ph I Study of Enbrel Biosimilar in China
Clover Initiates Ph I Study of Enbrel Biosimilar in China
CP Wire
Clover BioPharmaceuticals
Enbrel
Amgen
biosimilars
SCB-808
China
Flag link:
Amgen's new migraine drug hits insurance hurdles
Amgen's new migraine drug hits insurance hurdles
Reuters
Amgen
migraines
Aimovig
insurers
Flag link:
New drug sales power Amgen’s Q2 results
New drug sales power Amgen’s Q2 results
Alphastreet
Amgen
earnings
Flag link:
Amgen R&D chief Sean Harper hits the exits with a one-way ticket to early-stage biotech
Amgen R&D chief Sean Harper hits the exits with a one-way ticket to early-stage biotech
Endpoints
Amgen
R&D
Sean Harper
biotech
Flag link:
7 companies to watch during Q2 earnings
7 companies to watch during Q2 earnings
Biopharma Dive
earnings
Biogen
Gilead Sciences
Amgen
Celgene
AbbVie
Pfizer
Spark Therapeutics
Flag link:
Pfizer gets FDA approval for drug similar to Amgen's Neupogen
Pfizer gets FDA approval for drug similar to Amgen's Neupogen
Marketwatch
Pfizer
FDA
biosimilars
Amgen
Neupogen
Nivestym
Flag link:
Could Amgen soften the Neulasta biosimilar blow with an Alexion buy?
Could Amgen soften the Neulasta biosimilar blow with an Alexion buy?
Fierce Pharma
Amgen
biosimilars
Neulasta
Alexion
M&A
Flag link:
Amgen, UCB are back pitching once-rejected osteoporosis drug romo to the FDA — but big hurdles lie ahead
Amgen, UCB are back pitching once-rejected osteoporosis drug romo to the FDA — but big hurdles lie ahead
Endpoints
Amgen
UCB Pharma
osteoporosis
romosozumab
Flag link:
Amgen, Novartis 'overwhelmed' by early interest in migraine drug Aimovig: expert
Amgen, Novartis 'overwhelmed' by early interest in migraine drug Aimovig: expert
Fierce Pharma
migraines
Amgen
Novartis
Aimovig
Flag link:
Amgen Announces Top-Line Data From Remicade Biosimilar Study
Amgen Announces Top-Line Data From Remicade Biosimilar Study
Yahoo/Zacks.com
Amgen
ABP 710
JNJ
Merck
Remicade
biosimilars
rheumatoid arthritis
Flag link:
Amgen's Repatha Reduces Bad Cholestrol in Type II Diabetes
Amgen's Repatha Reduces Bad Cholestrol in Type II Diabetes
NASDAQ.com
Amgen
Repatha
type 2 diabetes
diabetes
hypercholesterolemia
ADA
Flag link:
Akero picks up $65M to advance Amgen-licensed NASH drug
Akero picks up $65M to advance Amgen-licensed NASH drug
Fierce Biotech
Akeron Therapeutics
NASH
Amgen
AKR-001
Flag link:
Novartis touts effectiveness, safety of autoimmune drug copies
Novartis touts effectiveness, safety of autoimmune drug copies
Yahoo/Reuters
Novartis
biosimilars
JNJ
Remicade
Amgen
Enbrel
autoimmune disease
Flag link:
Could an old Amgen-developed RA drug make CAR-T treatments safer?
Could an old Amgen-developed RA drug make CAR-T treatments safer?
Fierce Biotech
CAR-T
cytokine release syndrome
Kymriah
Yescarta
Amgen
Kineret
Flag link:
Migraine Breakthrough: Not So Fast
Migraine Breakthrough: Not So Fast
Forbes
Amgen
Novartis
Aimovig
migraines
adults
monoclonal antibodies
Flag link:
Amgen's $3.9B Neulasta to face U.S. biosim 'in the coming weeks' with Mylan approval
Amgen's $3.9B Neulasta to face U.S. biosim 'in the coming weeks' with Mylan approval
Fierce Pharma
FDA
Fulphila
Mylan Labs
biosimilars
Amgen
Neulasta
Flag link:
Amgen to ramp up early-stage immuno-oncology with 2 MD Anderson deals
Amgen to ramp up early-stage immuno-oncology with 2 MD Anderson deals
Fierce Biotech
Amgen
MD Anderson Cancer Center
drug development
blood cancers
Small-Cell Lung Cancer
Flag link:
FDA stalls yet another Herceptin copycat, issuing response letter to Amgen/Allergan
FDA stalls yet another Herceptin copycat, issuing response letter to Amgen/Allergan
Endpoints
Amgen
Allergan
FDA
complete response letter
biosimilars
Herceptin
ABP 980
Flag link:

Pages